iZafe Group AB Series B - Asset Resilience Ratio
iZafe Group AB Series B (IZAFE-B) has an Asset Resilience Ratio of 12.06% as of September 2025. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. Read iZafe Group AB Series B balance sheet liabilities for a breakdown of total debt and financial obligations.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio Trend (2016–2024)
This chart shows how iZafe Group AB Series B's Asset Resilience Ratio has changed over time. See iZafe Group AB Series B (IZAFE-B) shareholders funds for net asset value and shareholders' equity analysis.
Liquid Assets Composition Over Time
This chart breaks down iZafe Group AB Series B's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For market capitalisation and broader financial context, see IZAFE-B market cap.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | Skr4.85 Million | 12.06% |
| Short-term Investments | Skr0.00 | 0% |
| Total Liquid Assets | Skr4.85 Million | 12.06% |
Asset Resilience Insights
- Moderate Liquidity: iZafe Group AB Series B has 12.06% of assets in liquid form.
- While adequate for normal operations, this level may limit flexibility during economic stress.
- The company primarily holds liquidity in cash and equivalents rather than short-term investments.
iZafe Group AB Series B Industry Peers by Asset Resilience Ratio
Compare iZafe Group AB Series B's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
iRay Technology Co Ltd
SHG:688301 |
Medical Instruments & Supplies | 0.68% |
|
Nanosonics Ltd
AU:NAN |
Medical Instruments & Supplies | 51.82% |
|
Jiangsu Nanfang Medical
SHG:603880 |
Medical Instruments & Supplies | 2.27% |
|
Ansell Ltd
AU:ANN |
Medical Instruments & Supplies | 4.42% |
|
SDI Ltd
AU:SDI |
Medical Instruments & Supplies | 6.36% |
|
Austco Healthcare Ltd
AU:AHC |
Medical Instruments & Supplies | 15.90% |
|
Trajan Group Holdings Ltd
AU:TRJ |
Medical Instruments & Supplies | 0.23% |
|
Osteopore Ltd
AU:OSX |
Medical Instruments & Supplies | 43.09% |
Annual Asset Resilience Ratio for iZafe Group AB Series B (2016–2024)
The table below shows the annual Asset Resilience Ratio data for iZafe Group AB Series B.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2024-12-31 | 8.87% | Skr2.15 Million ≈ $231.37K |
Skr24.23 Million ≈ $2.61 Million |
-7.98pp |
| 2023-12-31 | 16.85% | Skr5.83 Million ≈ $627.83K |
Skr34.61 Million ≈ $3.73 Million |
+13.50pp |
| 2022-12-31 | 3.35% | Skr1.70 Million ≈ $183.05K |
Skr50.70 Million ≈ $5.46 Million |
-35.31pp |
| 2021-12-31 | 38.67% | Skr18.73 Million ≈ $2.02 Million |
Skr48.43 Million ≈ $5.21 Million |
+31.40pp |
| 2020-12-31 | 7.26% | Skr2.55 Million ≈ $274.21K |
Skr35.08 Million ≈ $3.78 Million |
-3.14pp |
| 2019-12-31 | 10.41% | Skr7.47 Million ≈ $803.57K |
Skr71.75 Million ≈ $7.72 Million |
+7.64pp |
| 2018-12-31 | 2.77% | Skr1.21 Million ≈ $129.89K |
Skr43.58 Million ≈ $4.69 Million |
-23.36pp |
| 2017-12-31 | 26.13% | Skr3.58 Million ≈ $385.70K |
Skr13.71 Million ≈ $1.48 Million |
-17.89pp |
| 2016-12-31 | 44.03% | Skr3.56 Million ≈ $383.44K |
Skr8.09 Million ≈ $870.88K |
-- |
About iZafe Group AB Series B
iZafe Group AB (publ), a medical technology company, engages in the research, development, and marketing of digital medical solutions and services for safer drug management at home. The company provides Dosell, an automated medication dispenser that handles medication pouches, smart pillboxes, facilitates and enables independent medication, and reminds and alerts in the scheduled doses. It also o… Read more